Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Toyama Chemical Files Solithromycin for ENT Infection Diseases
April 26, 2019
- Chugai Rings Up Record Q1 Earnings on Brisk New Drug Sales
April 25, 2019
- Boehringer’s Japan Ethical Drug Sales in 2018 Sink 18.4% on Micardis Cliff
April 25, 2019
- Mitsubishi Tanabe Slashes FY2018 Earnings Forecast
April 25, 2019
- Chugai to Erect New Manufacturing Building for Small, Middle Molecule APIs
April 25, 2019
- Over 170 Staffers to Quit Chugai at June-End: Voluntary Redundancy
April 25, 2019
- Kyowa Kirin Seeks Additional Indication for Orkedia
April 25, 2019
- Poxel’s Novel Diabetes Med One Step Closer to World’s 1st Launch, Japan Chief Says Physicians’ Trust Holds Key
April 24, 2019
- Aducanumab Termination Was Wrenching Decision: Eisai CEO
April 24, 2019
- In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs
April 24, 2019
- Teva Takeda to Shutter 2 Factories in Shiga
April 24, 2019
- Boehringer Seeks Additional Indication for Ofev
April 23, 2019
- Nippon Kayaku Grabs Japan Rights to Lilly’s Soon-to-Launch Portrazza
April 23, 2019
- Banned Doping Substance Contamination on API Production Line: Sawai Report
April 23, 2019
- MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
April 22, 2019
- SanBio Vows to Create In-House Marketing System in Japan by 2020, Eyes Global Leader by 2025: President
April 22, 2019
- Sumitomo Dainippon Cuts Sales Outlook for FY2018, Ups Profit Forecast
April 22, 2019
- Novartis to Begin Kymriah Treatment at 2-3 Japan Sites, Looks at Gradual Expansion
April 19, 2019
- Boehringer to Remain Major Employer in Japan with As-Needed Staffer Placement
April 19, 2019
- Chugai-Originated Eczema Drug Hits Primary Goal in Japan PIII: Maruho
April 19, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…